Literature DB >> 23978383

Decreased vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) function in knockout mice affects aging of dopaminergic systems.

F S Hall1, K Itokawa, A Schmitt, R Moessner, I Sora, K P Lesch, G R Uhl.   

Abstract

Dopamine (DA) is accumulated and compartmentalized by the dopamine transporter (DAT; SLC3A6) and the vesicular monoamine transporter 2 (VMAT2; SLC18A2). These transporters work at the plasma and vesicular membranes of dopaminergic neurons, respectively, and thus regulate levels of DA in neuronal compartments that include the extravesicular cytoplasmic compartment. DA in this compartment has been hypothesized to contribute to oxidative damage that can reduce the function of dopaminergic neurons in aging brains and may contribute to reductions in dopaminergic neurochemical markers, locomotor behavior and responses to dopaminergic drugs that are found in aged animals. The studies reported here examined aged mice with heterozygous deletions of VMAT2 or of DAT, which each reduce transporter expression to about 50% of levels found in wild-type (WT) mice. Aged mice displayed reduced locomotor responses under a variety of circumstances, including in response to locomotor stimulants, as well as changes in monoamine levels and metabolites in a regionally dependent manner. Several effects of aging were more pronounced in heterozygous VMAT2 knockout (KO) mice, including aging induced reductions in locomotion and reduced locomotor responses to cocaine. By contrast, some effects of aging were reduced or not observed in heterozygous DAT KO mice. These findings support the idea that altered DAT and VMAT2 expression affect age-related changes in dopaminergic function. These effects are most likely mediated by alterations in DA compartmentalization, and might be hypothesized to be exacerbated by other factors that affect the metabolism of cytosolic DA. This article is part of the Special Issue entitled 'The Synaptic Basis of Neurodegenerative Disorders'. Published by Elsevier Ltd.

Entities:  

Keywords:  Aging; Amphetamine; Cocaine; Dopamine; Gene knockout; Transgenic mice

Mesh:

Substances:

Year:  2013        PMID: 23978383      PMCID: PMC3811113          DOI: 10.1016/j.neuropharm.2013.07.031

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  114 in total

1.  Dopaminergic changes in the basal ganglia. A generalized phenomenon of aging in mammals.

Authors:  D G Morgan; C E Finch
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

2.  Age-related changes in nigrostriatal dopaminergic function in heterozygous mutant dopamine transporter knock-out mice.

Authors:  Dean E Dluzen; Jing Ji; Janet L McDermott
Journal:  Neurosci Lett       Date:  2010-04-09       Impact factor: 3.046

3.  Age-related changes in the nigrostriatum: a behavioral and biochemical analysis.

Authors:  J A Joseph; R E Berger; B T Engel; G S Roth
Journal:  J Gerontol       Date:  1978-09

4.  Overview of morphological changes in Parkinson's disease.

Authors:  K Jellinger
Journal:  Adv Neurol       Date:  1987

5.  Rate of cell death in parkinsonism indicates active neuropathological process.

Authors:  P L McGeer; S Itagaki; H Akiyama; E G McGeer
Journal:  Ann Neurol       Date:  1988-10       Impact factor: 10.422

6.  Selective alteration of mouse brain neurotransmitter release with age.

Authors:  G B Freeman; G E Gibson
Journal:  Neurobiol Aging       Date:  1987 Mar-Apr       Impact factor: 4.673

Review 7.  Differential decrease in the rate of dopamine synthesis in several dopaminergic neurons of aged rat brain.

Authors:  H Watanabe
Journal:  Exp Gerontol       Date:  1987       Impact factor: 4.032

8.  Influence of aging on catecholamine levels, accumulation, and release in F-344 rats.

Authors:  H H McIntosh; T C Westfall
Journal:  Neurobiol Aging       Date:  1987 May-Jun       Impact factor: 4.673

9.  Substrain differences of age-related changes in in vivo dopamine synthesis in the striatum and nucleus accumbens of the rat brain.

Authors:  H Watanabe
Journal:  J Pharmacobiodyn       Date:  1987-07

10.  Absence of alpha-synuclein affects dopamine metabolism and synaptic markers in the striatum of aging mice.

Authors:  Abdelmojib Al-Wandi; Natalia Ninkina; Steven Millership; Sally J M Williamson; Paul A Jones; Vladimir L Buchman
Journal:  Neurobiol Aging       Date:  2008-12-20       Impact factor: 4.673

View more
  12 in total

Review 1.  Dopamine transporter mutant animals: a translational perspective.

Authors:  Evgeniya V Efimova; Raul R Gainetdinov; Evgeny A Budygin; Tatyana D Sotnikova
Journal:  J Neurogenet       Date:  2016-03       Impact factor: 1.250

2.  Brexpiprazole reduces hyperactivity, impulsivity, and risk-preference behavior in mice with dopamine transporter knockdown-a model of mania.

Authors:  Morgane Milienne-Petiot; Mark A Geyer; Jørn Arnt; Jared W Young
Journal:  Psychopharmacology (Berl)       Date:  2017-02-03       Impact factor: 4.530

Review 3.  Methamphetamine Dysregulation of the Central Nervous System and Peripheral Immunity.

Authors:  Douglas R Miller; Mengfei Bu; Adithya Gopinath; Luis R Martinez; Habibeh Khoshbouei
Journal:  J Pharmacol Exp Ther       Date:  2021-09-17       Impact factor: 4.402

Review 4.  Neuron membrane trafficking and protein kinases involved in autism and ADHD.

Authors:  Yasuko Kitagishi; Akari Minami; Atsuko Nakanishi; Yasunori Ogura; Satoru Matsuda
Journal:  Int J Mol Sci       Date:  2015-01-30       Impact factor: 5.923

5.  Metabolism of Dopamine in Nucleus Accumbens Astrocytes Is Preserved in Aged Mice Exposed to MPTP.

Authors:  Brittany M Winner; Harue Zhang; McKenzie M Farthing; Lalitha M Karchalla; Keith J Lookingland; John L Goudreau
Journal:  Front Aging Neurosci       Date:  2017-12-12       Impact factor: 5.750

6.  Dopaminergic Dysfunction in Mammalian Dopamine Neurons Induced by Simazine Neurotoxicity.

Authors:  Xueting Li; Jia Yu; Jianan Li; Yanping Wu; Baixiang Li
Journal:  Int J Mol Sci       Date:  2017-11-13       Impact factor: 5.923

7.  Increased Vesicular Monoamine Transporter 2 (VMAT2) and Dopamine Transporter (DAT) Expression in Adolescent Brain Development: A Longitudinal Micro-PET/CT Study in Rodent.

Authors:  Donglang Jiang; Xiuhong Lu; Zijing Li; Nicklas Rydberg; Chuantao Zuo; Fangyu Peng; Fengchun Hua; Yihui Guan; Fang Xie
Journal:  Front Neurosci       Date:  2019-01-15       Impact factor: 4.677

Review 8.  Dopamine compartmentalization, selective dopaminergic vulnerabilities in Parkinson's disease and therapeutic opportunities.

Authors:  George R Uhl
Journal:  Ann Clin Transl Neurol       Date:  2019-01-08       Impact factor: 4.511

9.  The interactions of dopamine and oxidative damage in the striatum of patients with neurodegenerative diseases.

Authors:  Huifangjie Li; Pengfei Yang; William Knight; Yingqiu Guo; Joel S Perlmutter; Tammie L S Benzinger; John C Morris; Jinbin Xu
Journal:  J Neurochem       Date:  2019-11-04       Impact factor: 5.372

10.  Polymorphism in the Vesicular Monoamine Transporter 2 Gene Decreases the Risk of Parkinson's Disease in Han Chinese Men.

Authors:  Xinglong Yang; Pingrong Xu; Quanzhen Zhao; Ran An; Hua Jia; Zhuolin Liu; Yanming Xu
Journal:  Parkinsons Dis       Date:  2015-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.